ReviewFrontiers in pharmacology2020
First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
Review in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.Frontiers in medicine · 2021Pooled it
- How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.Technology in cancer research & treatmentPooled it
- A Phase I/IIa Randomized Trial Evaluating the Safety and Efficacy of SNK01 Plus Pembrolizumab in Patients with Stage IV Non-Small Cell Lung Cancer.Cancer research and treatment · 2022Trial
- Trends in the Overall Incidence and Mortality of Lung Cancer: An Extensive Longitudinal Study Utilizing the CDC WONDER Database 1999-2020.Thoracic cancer · 2026Article
- Immune checkpoints in lung cancer.Breathe (Sheffield, England) · 2026Review
- SPP1 promotes cancer stemness and reduces osimertinib sensitivity in non-small cell lung cancer through interactions with CD44.Cancer cell international · 2026Article
- Integrating differential gene expression and Mendelian randomization analyses reveal novel gene for prognosis, immune response, and drug sensitivity in lung cancer.Discover oncology · 2025Article
- A Novel Strategy for Enhancing Lung Cancer Immunotherapy Efficacy: Traditional Chinese Medicine Formula Shuyu Pills Enhances Anti-PD-1 Efficacy Via the "GM-ERS-Immunity" Axis.Biological procedures online · 2025Article
- Structure-activity relationship ofEJNMMI radiopharmacy and chemistry · 2025Article
- Investigation the immunotherapeutic potential of miR-4477a targeting PD-1/PD-L1 in breast cancer cell line using a CD8Molecular biology reports · 2025Article
- Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy.Experimental hematology & oncology · 2025Review
- Dendrobine Suppresses Tumor Growth by Regulating the PD-1/PD-L1 Checkpoint Pathway in Lung Cancer.Current cancer drug targets · 2025Article
- Immune Cell Homing Hydrogels for Cancer Immunotherapy.Methods in molecular biology (Clifton, N.J.) · 2025Article
- The Impact of Genetic Mutations on the Efficacy of Immunotherapies in Lung Cancer.International journal of molecular sciences · 2024Review
- Article
- Modulating Tumor Immunity by Targeting Tumor Fibrotic Stroma and Angiogenic Vessels for Lung Cancer Treatment.Cancers · 2024Article
- Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.Journal of thoracic disease · 2024Article
- Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands.EJNMMI radiopharmacy and chemistry · 2024Article
- A replicating LCMV-based vaccine for the treatment of solid tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Design, Synthesis, and Biological Evaluation of Small-Molecule-Based Radioligands with Improved Pharmacokinetic Properties for Imaging of Programmed Death Ligand 1.Journal of medicinal chemistry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most common cancers and the leading cause of cancer-related deaths worldwide. Most of these patients with non-small cell lung cancer (NSCLC) present with the advanced stage of the disease at the time of diagnosis, and thus decrease the 5-year survival rate to about 5%. Immune checkpoint inhibitors (ICIs) can act on the inhibitory pathway of cancer immune response, thereby restoring and maintaining anti-tumor immunity. There are already ICIs targeting different pathways, including the programmed cell death 1 (PD-1), programmed cell death ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA-4) pathway. Since March 2015, the US Food and Drug Administration (FDA) approved nivolumab (anti-PD-1 antibody) as the second-line option for treatment of patients with advanced squamous NSCLC. Additionally, a series of inhibitors related to PD-1/PD-L1 immune-checkpoints have helped in the immunotherapy of NSCLC patients, and modified the original treatment model. However, controversies remain regarding the use of ICIs in a subgroup with targeted oncogene mutations is a problem that we need to solve. On the other hand, there are continuous efforts to find biomarkers that effectively predict the response of ICIs to screen suitable populations. In this review, we have reviewed the history of the continuous developments in cancer immunotherapy, summarized the mechanism of action of the immune-checkpoint pathways. Finally, based on the results of the first-line recent trials, we propose a potential first-line immunotherapeutic strategy for the treatment of the patients with NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.